Processa Pharmaceuticals logo
Processa Pharmaceuticals
PCSA | NASDAQ
Chart Builder DCF Calculator
$1.72
-$0.14 (-7.53%)
At close: Nov 16, 2026, 4:00 PM ET
$1.72
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:54 PM ET

Processa Pharmaceuticals Company Profile

Company profile explained

Company Profile

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

Key Executives

Name Position
George K. Ng Chief Executive Officer & Director
Russell L. Skibsted Chief Financial Officer
David Young Co-Founder, President of Research and Development & Director
Patrick Lin Co-Founder, Chief Business & Strategy Officer
Steven Cha Senior Vice President of Clinical Research
Wendy J. Guy Co-Founder, Chief Administrative Officer & Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 23, 2026 EFFECT Filing
Oct 22, 2026 DEF 14A Filing
Oct 09, 2026 PRE 14A Filing
Oct 09, 2026 PRE 14A Filing
Oct 09, 2026 S-3 Filing
Oct 05, 2026 8-K/A [Amend] Current Report
Aug 18, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 14, 2026 10-Q Quarterly Report
Aug 11, 2026 4 Filing
View All SEC Filings ➞
Processa Pharmaceuticals
Processa Pharmaceuticals logo
Country United States
IPO Date Mar 7, 2014
Industry Biotechnology
Sector Healthcare
Employees 12
CEO George K. Ng

Contact Details

601 21st Street Vero Beach, Florida 32960 United States

Stock Details

Ticker Symbol PCSA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001533743
CUSIP Number 74275C403
ISIN Number US74275C4033
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.